Adicet Bio, Inc.
NASDAQ Global MarketTotal Valuation
Adicet Bio, Inc. carries a market capitalization of 77.31M, placing it among publicly traded companies globally. Its enterprise value stands at -24.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 77.31M |
| Enterprise Value | -24.45M |
Share Statistics
Adicet Bio, Inc. currently has 9.36M shares outstanding.
| Shares Outstanding | 9.36M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | -0.96 |
| P/OCF Ratio | -0.96 |
Financial Position
Adicet Bio, Inc. maintains a current ratio of 6.71, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.70, indicating elevated leverage, while an interest coverage ratio of -1,211.38 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.71 |
| Quick Ratio | 6.59 |
| Debt / Equity | 10.70 |
| Debt / EBITDA | -0.13 |
| Interest Coverage | -1,211.38 |
Financial Efficiency
| Return on Equity (ROE) | -78.08 |
| Return on Assets (ROA) | -63.62 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 143,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Adicet Bio, Inc.'s stock has declined approximately -38.37556% over the past 52 weeks. The 50-day moving average sits at 8.81, while the 200-day moving average is 8.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | -38.37556% |
| 50-Day Moving Average | 8.81 |
| 200-Day Moving Average | 8.05 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -98.12M, while operating income came in at -103.71M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -103.71M |
| Pretax Income | -98.83M |
| Net Income | -98.97M |
| EBITDA | -98.12M |
| EBIT | -103.71M |
| Earnings Per Share (EPS) | -10.54 |
Balance Sheet
Adicet Bio, Inc. holds 118.19M in cash and equivalents against 12.85M in total debt, resulting in a net debt position of -33.13M. Total book value stands at 120.14M, with working capital of 102.76M providing operational flexibility.
| Cash & Cash Equivalents | 118.19M |
| Total Debt | 12.85M |
| Net Debt | -33.13M |
| Equity (Book Value) | 120.14M |
| Book Value Per Share | 12.83 |
| Working Capital | 102.76M |
Cash Flow
Adicet Bio, Inc. produced -84.53M in operating cash flow over the past twelve months. After subtracting -438,000.00 in capital expenditures, free cash flow totaled -84.97M - equivalent to -9.05 per share.
| Operating Cash Flow | -84.53M |
| Capital Expenditures | -438,000.00 |
| Free Cash Flow | -84.97M |
| FCF Per Share | -9.05 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -92.82 |
| FCF Yield | -103.68 |
Stock Splits
Adicet Bio, Inc.'s most recent stock split took place on December 30, 2025 with a 16:1 split ratio.
| Last Split Date | 12/30/2025 |
| Split Ratio | 16:1 |
Scores
Adicet Bio, Inc. posts an Altman Z-Score of -5.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.95 |